To investigate whether BTLA is involved in resistance to PD-1/PD-L1 blockade therapy, we performed in vivo treatment with PD-1/PD-L1 antibodies in Lewis lung carcinoma (LLC)-derived murine NSCLC model. The gene discussed is BTLA; the disease is non-small cell lung carcinoma.